Preventing all‐cause hospitalizations in type 2 diabetes with sodium‐glucose cotransporter‐2 inhibitors and <scp>glucagon‐like peptide</scp> ‐1 receptor agonists: A narrative review and proposed clinical approach-Reference-Cited by-同舟云学术

Preventing all‐cause hospitalizations in type 2 diabetes with sodium‐glucose cotransporter‐2 inhibitors and glucagon‐like peptide ‐1 receptor agonists: A narrative review and proposed clinical approach

Published:2022-03-24 Issue:6 Volume:24 Page:969-982
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obesity Metabolism

Author:

Schechter Meir¹²^ORCID,Fischer Matan¹³⁴,Mosenzon Ofri¹²^ORCID

Affiliation:

1. Faculty of Medicine Hebrew University of Jerusalem Jerusalem Israel

2. Diabetes Unit, Department of Endocrinology and Metabolism Hadassah Medical Center Jerusalem Israel

3. Department of Endocrinology and Metabolism Hadassah Medical Center Jerusalem Israel

4. Department of internal medicine B Hadassah Medical Center Jerusalem Israel

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14675

Reference117 articles.

1. Reasons for hospitalizations in patients with type 2 diabetes in the CANVAS programme: A secondary analysis

2. Trends in leading causes of hospitalisation of adults with diabetes in England from 2003 to 2018: an epidemiological analysis of linked primary care records

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of empagliflozin on first and recurrent events leading to or prolonging hospitalisation in the EMPA-REG OUTCOME trial;Diabetes Research and Clinical Practice;2024-06

2. Risk of hospitalization with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes lacking evidence of chronic kidney disease: Real‐world data;Diabetes, Obesity and Metabolism;2023-06-29

3. The growing clinical effect of SGLT2 inhibitors;The Lancet Diabetes & Endocrinology;2023-04

4. Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial;The Lancet Diabetes & Endocrinology;2023-04

5. Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease;Annals of Internal Medicine;2023-01